CARDIOMETABOLIC RISK TRAJECTORIES ON AND AFTER ANTI-OBESITY MEDICATION USE: A CLAIMS-BASED ANALYSIS
Author(s)
Lilah Khoja, MPH, PhD1, Mohammad S. Alnuman, BSc, MS2, Kibum Kim, PhD3;
1University of Illinois at Chicago Department of Pharmacy Systems, Outcomes, and Policy, HEOR Takeda Fellow, Chicago, IL, USA, 2University of Illinois at Chicago Department of Pharmacy Systems, Outcomes, and Policy, Chicago, IL, USA, 3UIC College of Pharmacy, Chicago, IL, USA
1University of Illinois at Chicago Department of Pharmacy Systems, Outcomes, and Policy, HEOR Takeda Fellow, Chicago, IL, USA, 2University of Illinois at Chicago Department of Pharmacy Systems, Outcomes, and Policy, Chicago, IL, USA, 3UIC College of Pharmacy, Chicago, IL, USA
OBJECTIVES: Incretin memetics used as anti-obesity medications (AOM) have become standard pharmacologic adjunct strategy for weight loss and management. However, health profiles during active AOM and after AOM discontinuation in real-world setting have yet to be understood. We examined the cardiometabolic (CM) risk trajectories of patients during AOM use and after discontinuation.
METHODS: A retrospective, observational study was conducted using Merative MarketScan health claims linked with the self-reported Health Risk Assessment data. Adults aged > 18 who filled incretin memetic AOMs between January 2016 and September 2024 were included in the analysis. Discontinuation was defined by the end of the AOM supply. Individuals with records for body mass index (BMI; kg/m2), systolic blood pressure (SBP; mmHg), or total blood glucose (BGL; mg/DL) were eligible for inclusion. Using SAS, population-averaged linear models with generalized estimating equations were fit to estimate the change in BMI, SBP, and BGL for 6-months during and post-AOM use.
RESULTS: The cohort included 1,722 patients, with a mean (SD) age of 46.74 (9.59). The majority of the patients were female (83.12%). During treatment, BMI decreased by 0.52 points per month (95 CI: -0.61 - -0.39, p<0.01). After discontinuation, BMI increased by 0.04 points per month (95 CI: -0.12 - 0.20, p=0.63). During treatment, the monthly SBP and BGL chances were -0.64 mmHg (95 CI: -1.39 - 0.11, p=0.096) and -3.45 mg/DL (95 CI: -5.90 - -1.00, p<0.01) . After discontinuation, the respective SBP and BGL changes were +0.14 mmHg (95 CI: -0.84 - 1.11, p=0.78) and +3.47 mg/DL (95 CI: -0.29 - 7.24, p=0.07).
CONCLUSIONS: The significant cardiometabolic health improvements observed during AOM use are aligned with trial data. However, an immediate attenuation or loss of benefit was observed upon discontinuation. Further studies into the AOM discontinuation and its impacts are warranted to support efficient AOM use.
METHODS: A retrospective, observational study was conducted using Merative MarketScan health claims linked with the self-reported Health Risk Assessment data. Adults aged > 18 who filled incretin memetic AOMs between January 2016 and September 2024 were included in the analysis. Discontinuation was defined by the end of the AOM supply. Individuals with records for body mass index (BMI; kg/m2), systolic blood pressure (SBP; mmHg), or total blood glucose (BGL; mg/DL) were eligible for inclusion. Using SAS, population-averaged linear models with generalized estimating equations were fit to estimate the change in BMI, SBP, and BGL for 6-months during and post-AOM use.
RESULTS: The cohort included 1,722 patients, with a mean (SD) age of 46.74 (9.59). The majority of the patients were female (83.12%). During treatment, BMI decreased by 0.52 points per month (95 CI: -0.61 - -0.39, p<0.01). After discontinuation, BMI increased by 0.04 points per month (95 CI: -0.12 - 0.20, p=0.63). During treatment, the monthly SBP and BGL chances were -0.64 mmHg (95 CI: -1.39 - 0.11, p=0.096) and -3.45 mg/DL (95 CI: -5.90 - -1.00, p<0.01) . After discontinuation, the respective SBP and BGL changes were +0.14 mmHg (95 CI: -0.84 - 1.11, p=0.78) and +3.47 mg/DL (95 CI: -0.29 - 7.24, p=0.07).
CONCLUSIONS: The significant cardiometabolic health improvements observed during AOM use are aligned with trial data. However, an immediate attenuation or loss of benefit was observed upon discontinuation. Further studies into the AOM discontinuation and its impacts are warranted to support efficient AOM use.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO51
Topic
Clinical Outcomes
Topic Subcategory
Relating Intermediate to Long-term Outcomes
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity)